Accelerate Diagnostics Revenue, Profits - AXDX Quarterly Income Statement

Add to My Stocks
$22.4 $0.3 (1.32%) AXDX stock closing price Sep 25, 2017 (Closing)

Fundamental analysis of AXDX stock involves analyzing its financial statements, apart from checking the Accelerate Diagnostics stock price The income statement is a summary of the revenue or sales, expenses and profitability (shown as Net Income) or lack of it. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase of $0.7M for 2017-Q2 impacts the AXDX stock. Investors typically check year over year or quarter over quarter revenue growth. One also needs to look at Accelerate Diagnostics assets, operating expenses and Accelerate Diagnostics free cash flow. The Accelerate Diagnostics profit and loss statement shows revenue of $0.7M for 2017-Q2. Revenue has grown by $0.2M QoQ for AXDX stock. View details of revenue and profits for Accelerate Diagnostics for latest & last 40 quarters

show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec.2017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q32015 Q22015 Q1
Accelerate Diagnostics Net Sales or Revenues
0.7M0.5M0.04M0.02M0.02M0.16M0.02M0.09M0.02M0.01M
Cost Of Goods Sold (COGS)0.13M0.02M--------
Accelerate Diagnostics Gross Profit
0.56M0.5M0.04M0.02M0.02M0.16M0.03M0.09M0.01M0.01M
Research & Development Expense5.52M4.28M5.25M7.53M8.06M7.35M6.04M6.49M7.12M6.37M
Selling General & Admin Expense11.46M10.52M10.24M9.3M9.23M7.43M5.94M4.33M4.75M2.86M
Income Before Depreciation Depletion Amortization-16.42M-14.31M-15.44M-16.81M-17.28M-14.62M-11.93M-10.73M-11.86M-9.23M
Depreciation Depletion Amortization--0.61M0.6M0.6M0.54M0.61M0.46M0.4M0.32M
Non Operating Income0.14M0.11M0.19M0.11M0.02M0.09M0.03M0.02M0.01M0.01M
Interest Expense0.01M-0.02M---0.02M---
Accelerate Diagnostics Pretax Income
-16.28M-14.2M-15.88M-17.29M-17.86M-15.07M-12.52M-11.18M-12.25M-9.54M
Provision for Income Taxes0.17M-0.26M---0.64M---0.64M
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-16.46M-14.2M-16.14M-17.3M-17.87M-15.07M-13.16M-11.82M-12.25M-8.9M
Extraordinary Items & Discontinued Operations----------
Accelerate Diagnostics Net Income (Profit/Loss)
-16.46M-14.2M-16.14M-17.3M-17.87M-15.07M-13.16M-11.82M-12.25M-8.9M
Average Shares used to compute Diluted EPS53.57M51.89M52.05M51.24M51.21M51.2M45M44.73M44.68M44.65M
Average Shares used to compute Basic EPS53.57M51.89M52.05M51.24M51.21M51.2M45M44.73M44.68M44.65M
Income Before Nonrecurring Items-16.46M-14.2M-16.14M-17.3M-17.87M-15.07M-13.16M-11.82M-12.25M-8.9M
Income from Nonrecurring Items----------
Accelerate Diagnostics Earnings Per Share Basic Net
-0.31-0.27-0.31-0.34-0.35-0.29-0.29-0.25-0.27-0.20
Accelerate Diagnostics Earnings Per Share Diluted Net
-0.31-0.27-0.31-0.34-0.35-0.29-0.29-0.25-0.27-0.20
EPS Diluted Before Nonrecurring Items-0.31-0.27-0.31-0.34-0.35-0.29-0.29-0.25-0.27-0.20
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Accelerate Diagnostics stock analysis involves checking at least a few of the important things like:
  • Revenue: This is the inflow that is generated from the sale of goods or services and is $0.7M for this quarter of 2017-Q2. Our Accelerate Diagnostics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. AXDX stock had a healthy bottom line growth.
The income statement is also called statement of revenue and expense. The AXDX financials along with Accelerate Diagnostics historical stock prices provide a lot of details about the firm .

Accelerate Diagnostics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
952.36
Dividend Yield
0%